Adjuvant treatment in operable breast cancer

Area of Science:

• Oncology
• Clinical Medicine
• Breast Cancer Research

Background:

• Adjuvant therapy is crucial for improving outcomes in postmenopausal women with breast cancer and axillary node metastases.
• The Ludwig III trial aimed to evaluate the efficacy of different adjuvant treatment regimens.

Purpose of the Study:

• To compare chemo-endocrine therapy (CMFp + T) with endocrine therapy (p + T) and no adjuvant treatment.
• To assess the impact of adjuvant therapy on survival and recurrence in this patient group.

Main Methods:

• A randomized trial involving 463 postmenopausal women (≤65 years) with breast cancer and axillary node metastases.
• Patients received either CMFp + T, p + T, or no adjuvant treatment after total mastectomy and axillary clearance.
• Treatment outcomes were analyzed based on prognostic factors.

Main Results:

• Chemo-endocrine therapy (CMFp + T) did not demonstrate a significant advantage over endocrine therapy (p + T) or no adjuvant treatment.
• Nodal status and primary tumor receptor content were identified as significant prognostic indicators.
• Tumor size was not found to be a significant prognostic factor in this study.

Conclusions:

• The addition of chemotherapy to endocrine therapy did not significantly improve outcomes for postmenopausal women with node-positive breast cancer.
• Nodal status and receptor content are critical for predicting prognosis in breast cancer patients.
• Further research may be needed to optimize adjuvant treatment strategies for specific patient subgroups.